Model‐based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challenges
暂无分享,去创建一个
[1] Wei Zhang,et al. An adaptive dose‐finding design incorporating both toxicity and efficacy , 2006, Statistics in medicine.
[2] P. Thall,et al. Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs , 2004, Biometrics.
[3] V. Fedorov,et al. Adaptive designs for dose-finding based on efficacy–toxicity response , 2006 .
[4] Anastasia Ivanova,et al. A New Dose‐Finding Design for Bivariate Outcomes , 2003, Biometrics.
[5] Mourad Tighiouart,et al. Translation of innovative designs into phase I trials. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Edward L Korn,et al. Dose escalation trial designs based on a molecularly targeted endpoint , 2005, Statistics in medicine.
[7] John O'Quigley,et al. Consistency of continual reassessment method under model misspecification , 1996 .
[8] S. Goodman,et al. Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.
[9] Daniel J Sargent,et al. An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations , 2007, Statistics in medicine.
[10] J O'Quigley,et al. Dose‐Finding Designs for HIV Studies , 2001, Biometrics.
[11] Anastasia Ivanova,et al. Two‐Dimensional Dose Finding in Discrete Dose Space , 2005, Biometrics.
[12] You-Gan Wang,et al. Decision‐theoretic designs for dose‐finding clinical trials with multiple outcomes , 2006, Statistics in medicine.
[13] P F Thall,et al. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. , 1998, Biometrics.
[14] Yu Shen,et al. A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose‐Finding Trial , 2005, Biometrics.
[15] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[16] P. Linsley. New look at an old costimulator , 2005, Nature Immunology.
[17] Yuan Ji,et al. Bayesian Dose‐Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios , 2006, Biometrics.
[18] M. Harris. Monoclonal antibodies as therapeutic agents for cancer. , 2004, The Lancet. Oncology.
[19] Thomas M Braun,et al. The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes. , 2002, Controlled clinical trials.
[20] A. Agresti. Categorical data analysis , 1993 .
[21] S Zacks,et al. Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.
[22] Sarah Zohar,et al. Recent Developments in Adaptive Designs for Phase I/II Dose-Finding Studies , 2007, Journal of biopharmaceutical statistics.
[23] B E Storer,et al. Design and analysis of phase I clinical trials. , 1989, Biometrics.
[24] Shyamal D Peddada,et al. Designs for Single‐ or Multiple‐Agent Phase I Trials , 2004, Biometrics.